BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tofacitinib: Additional Phase III data

Pfizer said that 4 deaths were reported in the double-blind, placebo-controlled, international Phase III ORAL Sync (1046) trial evaluating twice-daily 5 and 10 mg oral tofacitinib. One of the deaths - a case of respiratory failure - was determined to be related to tofacitinib. The 3 reported deaths that were determined not to be related to tofacitinib included 1 case of brain injury following trauma 22 days after discontinuation of tofacitinib; 1 case of worsening RA 42 days after discontinuation of tofacitinib; and 1 case of acute heart failure. Pfizer...

Read the full 428 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >